Therapeutic potential of "rexinoids" in cancer prevention and treatment.
Retinoid X receptor (RXR) is a combinatorial partner for one third of the 48 human nuclear receptor superfamily members and acts as a master coordinator of nuclear receptor signaling pathways involved in the control of cell growth and differentiation. Thus, ligand-dependent simultaneous activation of multiple pathways is an attractive strategy for molecular-targeted therapy of neoplastic disease. However, clinical trials in RXR-targeted molecular therapy with the RXR ligand (rexinoid) have yielded disappointing outcomes. In this review, we discuss a possible mechanism underlying the loss of sensitivity to rexinoid therapy.
Tanaka
Takemi
T
University of Texas Health Science Center, Institute of Molecular Medicine, Houston, Texas 77030, USA. Takemi.Tanaka@uth.tmc.edu
De Luca
Luigi M
LM
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001483:Base Sequence; D006801:Humans; D008024:Ligands; D009369:Neoplasms / Q000188:drug therapy* / Q000517:prevention & control*; D047488:Retinoid X Receptors / Q000187:drug effects* / Q000378:metabolism
D000970:Antineoplastic Agents; D008024:Ligands; D047488:Retinoid X Receptors